search
Back to results

Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
10 mg MK-0941 DFC (fasted)
10 mg MK-0941 OCT (after meal)
10 mg MK-0941 OCT (before meal)
10 mg MK-0941 OCT (fasted)
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males or females (of non-childbearing potential) between the ages of 18 to 70
  • Participants have been diagnosed with Type 2 Diabetes
  • Participants are nonsmokers for at least 6 months

Exclusion Criteria:

  • Participant should not be diagnosed with Type 1 diabetes
  • Participant should not be receiving insulin or PPAR gamma agonists for 12 weeks prior to study start
  • Participant has a recent history of eye infection or other inflammatory eye condition within 2 weeks prior to study start
  • Participant has been diagnosed with glaucoma or is blind
  • Participant has had trauma to one or both eyes
  • Participant has had major surgery, donated blood or participated in another clinical study in the past 4 weeks
  • Participant is a regular user of illicit drugs or has a history of drug, including alcohol, abuse in the past 6 months

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Experimental

    Active Comparator

    Arm Label

    DFC (fasted)

    OCT (fasted)

    OCT (after meal)

    OCT (before meal)

    Arm Description

    Outcomes

    Primary Outcome Measures

    Area Under the Curve (AUC)(0-∞) for Oral Compressed Tablet (OCT) (Fasted) and Dry Filled Capsule (DFC) (Fasted)
    Maximum Concentration (Cmax) for OCT (Fasted) and DFC (Fasted)
    Time to Reach Cmax (Tmax) for OCT (Fasted) and DFC (Fasted)
    Half Life (t½) for OCT (Fasted) and DFC (Fasted)

    Secondary Outcome Measures

    AUC(0-∞) for OCT (Fasted) and OCT (After Meal)
    Cmax of OCT (Fasted) and OCT (After Meal)
    Tmax for OCT (Fasted) and OCT (After Meal)
    t1/2 for OCT (Fasted) and OCT (After Meal)

    Full Information

    First Posted
    November 30, 2007
    Last Updated
    March 12, 2015
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00567112
    Brief Title
    Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)
    Official Title
    An Open-Label, Randomized, Partially Fixed-Sequence, 4-Period Crossover Study to Assess the Pharmacokinetics After Administration of the DFC and OCT Formulations and the Food Effect on the OCT Formulation of MK-0941 in Patients With Type 2 Diabetes
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2007 (undefined)
    Primary Completion Date
    February 2008 (Actual)
    Study Completion Date
    April 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    A study to compare the pharmacokinetics (PK) of the dry filled capsule (DFC) & oral compressed tablet (OCT) formulations of MK-0941-009 & to assess the effect of food on the OCT formulation.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    18 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    DFC (fasted)
    Arm Type
    Experimental
    Arm Title
    OCT (fasted)
    Arm Type
    Experimental
    Arm Title
    OCT (after meal)
    Arm Type
    Experimental
    Arm Title
    OCT (before meal)
    Arm Type
    Active Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    10 mg MK-0941 DFC (fasted)
    Intervention Description
    single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
    Intervention Type
    Drug
    Intervention Name(s)
    10 mg MK-0941 OCT (after meal)
    Intervention Description
    single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
    Intervention Type
    Drug
    Intervention Name(s)
    10 mg MK-0941 OCT (before meal)
    Intervention Description
    single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
    Intervention Type
    Drug
    Intervention Name(s)
    10 mg MK-0941 OCT (fasted)
    Intervention Description
    single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
    Primary Outcome Measure Information:
    Title
    Area Under the Curve (AUC)(0-∞) for Oral Compressed Tablet (OCT) (Fasted) and Dry Filled Capsule (DFC) (Fasted)
    Time Frame
    From study drug administration to 72 hours post-administration
    Title
    Maximum Concentration (Cmax) for OCT (Fasted) and DFC (Fasted)
    Time Frame
    From study drug administration to 72 hours post-administration
    Title
    Time to Reach Cmax (Tmax) for OCT (Fasted) and DFC (Fasted)
    Time Frame
    From study drug administration to 72 hours post-administration
    Title
    Half Life (t½) for OCT (Fasted) and DFC (Fasted)
    Time Frame
    From study drug administration to 72 hours post-administration
    Secondary Outcome Measure Information:
    Title
    AUC(0-∞) for OCT (Fasted) and OCT (After Meal)
    Time Frame
    From study drug administration to 72 hours post-administration
    Title
    Cmax of OCT (Fasted) and OCT (After Meal)
    Time Frame
    From study drug administration to 72 hours post-administration
    Title
    Tmax for OCT (Fasted) and OCT (After Meal)
    Time Frame
    From study drug administration to 72 hours post-administration
    Title
    t1/2 for OCT (Fasted) and OCT (After Meal)
    Time Frame
    From study drug administration to 72 hours post-administration

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Males or females (of non-childbearing potential) between the ages of 18 to 70 Participants have been diagnosed with Type 2 Diabetes Participants are nonsmokers for at least 6 months Exclusion Criteria: Participant should not be diagnosed with Type 1 diabetes Participant should not be receiving insulin or PPAR gamma agonists for 12 weeks prior to study start Participant has a recent history of eye infection or other inflammatory eye condition within 2 weeks prior to study start Participant has been diagnosed with glaucoma or is blind Participant has had trauma to one or both eyes Participant has had major surgery, donated blood or participated in another clinical study in the past 4 weeks Participant is a regular user of illicit drugs or has a history of drug, including alcohol, abuse in the past 6 months
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

    We'll reach out to this number within 24 hrs